SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs DefenCath could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and sales. Traders dispute how conclusive DaVitas estimate is, pointing to CMSs finalized payment rate and arguing the outlook depends on quarterly calculations and DefenCath uptake.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put Precigens PAPZIMEOS under scrutiny, with traders debating whether the new option will erode its market position. Some fear stronger competition, while others point to Precigens first-mover and full-approval advantages and question Inovios ability to commercialize its drug.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by Eylea HD and Dupixent-related collaboration revenue, are driving a sharp breakout to multiyear highs. Traders are broadly bullish on the results and follow-through, while some question whether the gains will hold.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is drawing attention after Brazil approved its Valaris merger, which traders see as a step toward closing the deal, alongside recent offshore contract wins and higher day-rate expectations. Bulls anticipate improved scale and a potential short squeeze, while skeptics point to merger-related dilution, debt and the upcoming earnings report.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys integration with Metas Muse AI agent, which can route purchases through Shop Pay, has fueled discussion about whether agentic commerce will expand Shopifys role in online shopping or threaten traditional storefronts. Traders are also debating the stocks sharp, volatile pullback, with some looking ahead to earnings and others concerned about valuation and whether AI-related growth will translate into revenue.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rebound and resilience amid broader crypto weakness and Binance hack fears have traders highlighting its privacy features and speculating about a safe-haven shift into ZEC; some also point to the upcoming NU7 upgrade. Others view the rally as overextended and expect further declines.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report and higher full-year revenue outlook, powered by demand for Mounjaro and Zepbound, have fueled LLYs rally and record highs. Traders are largely positive and cite analyst upgrades, while some question the valuation and point to trimmed profit guidance tied to acquisition-related research charges.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to a fresh 52-week high ahead of an expected quarterly report has traders focused on BRIUMVI growth and whether results can justify the run; some expect an earnings-driven move, while others warn the stock may be priced for a beat. Buyout speculation and possible short covering are also fueling bullish chatter, but no deal is confirmed and the earnings timing remains uncertain.

BankrCoin (BNKR) is a cryptocurrency and operates on the Base platform. BankrCoin has a current supply of 100,000,000,000 with 99,389,999,999.99966667 in circulation. The last known price of BankrCoin is 0.00029512 USD and is up 9.48 over the last 24 hours. It is currently trading on 84 active market(s) with $2,292,823.67 traded over the last 24 hours. More information can be found at https://warpcast.com/bankr.

BankrCoin

Traders are focused on Bankrs expanding AI-agent infrastructure and ecosystem integrations, alongside claims of protocol revenue, staking rewards and token buybacks that could support BNKR demand. Sentiment is largely bullish and accumulation-oriented, though some traders question whether the sharp moves are sustainable or speculative.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly results beat expectations, with record refining performance benefiting from tight diesel supplies amid geopolitical disruptions. Traders are broadly positive on the refining-led strength and shareholder returns, while some question whether the unusually strong margins can last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHWY Stock Hits Over 1-Month Low After Flat Q2 Gross Margin Overshadows Raised Outlook

Equity

Chewy raised its full-year outlook after Q2 sales grew 7.3%, but flat gross margin, an effectively in-line EPS print and weaker liquidity drew investor attention.

CHWY Stock Drops As CEO Flags Risks Around Consumer Spending

Chewy’s CEO sees that households are feeling “more stretched” these days.

Chewy CEO Flags Flat Pricing, Rising E-Commerce Shift And AI Push As Pet Care Industry Holds Course Into 2026

Sumit Singh stated on the fourth-quarter earnings call that 2026 is expected to mirror 2025, with steady demand and stable pet-ownership trends.


Chewy Shareholder BC Partners To Sell $1B Shares: Retail Mood Drops

Chewy won't receive any proceeds from the sale but has agreed to buy from the BC Partners funds $100 million worth of shares to be canceled upon completion of the deal.


Chewy Shares Drop Despite Strong Quarterly Results, Forecast: Retail Bets On Quick Recovery

CEO Sumit Singh says the pet segment is resilient, and Chewy will continue to gain market share.


Chewy Analyst Steps To Sidelines On Valuation Concerns — Retail Agrees

The pet supplies retailer has bucked the tariff-driven downturn in the market, with its shares rising nearly 42% year-to-date.


Retail Bulls Bite Into Chewy Stock As Q4 Results, 2025 Outlook Impress Amid Market Selloff

Chewy’s Autoship program, which allows users to schedule recurring deliveries of pet supplies, has supported sales growth in the past few quarters. Last year, the company also launched pet clinics.

Chewy Stock Slips Ahead Of Q4 Print, Retail Bets Pet Care Stays Shielded From Trump Tariffs

Chewy has been navigating a competitive pet e-commerce market, benefiting from strong customer loyalty and subscription-based sales but facing challenges from slowing consumer spending and rising costs.

How Is Zoetis’ Stock Performance Compared to Other Pet Care Stocks?

Zoetis has notably lagged behind other pet care stocks over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Do Wall Street Analysts Like IDEXX Laboratories Stock?

IDEXX Laboratories has significantly outperformed the broader market in 2025 and analysts remain bullish on the stock’s prospects.

ProShares Trust - ProShares Pet Care ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Chewy’s Q2 net sales rose 7.3% to $3.33 billion, while gross margin stayed flat at 30.4%.</li><li>Adjusted diluted EPS of $0.36 was in line with consensus, while adjusted EBITDA of $226.7 million topped FiscalAI estimate.</li><li>Chewy raised FY26 sales guidance to $13.46 billion to $13.57 billion and narrowed adjusted EBITDA margin guidance to 6.7% to 6.8%.</li></ul>Chewy Inc. (CHWY) stock fell&nbsp;in morning trade on Wednesday, putting shares on track to hit&nbsp;an over one-month low, even as the company reported higher second-quarter sales and raised its full-year outlook.The online pet retailer’s net sales increased 7.3% year on year to $3.33 billion,&nbsp;meeting Wall Street’s consensus estimate as per FiscalAI.&nbsp;Adjusted diluted earnings per share (EPS) rose to $0.36 from $0.33, missing FiscalAI’s estimate by roughly 1%.<a href="https://stocktwits.com/symbol/CHWY">CHWY stock</a> fell as much as 7% in morning trade,&nbsp;hitting levels last seen in late-July, and&nbsp;was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Sales Rise, But Gross Margin Stays Flat</h2>Chewy’s cost of goods sold (COGS) increased to $2.319 billion from $2.162 billion, a 7.3% rise that nearly matched sales growth, leaving gross margin unchanged at 30.4%&nbsp;in the second quarter (Q2).Profitability below the gross-margin line was stronger. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) jumped 23.7% to $226.7 million, with adjusted EBITDA margin expanding 90 basis points to 6.8%.<h2 class="st-heading-2">Chewy Raises Full-Year Outlook</h2>“The durability of our recurring revenue base, continued customer growth, and disciplined execution give us confidence to raise our full-year revenue and profitability outlook,” said Chewy CEO Sumit Singh.Chewy now expects FY26 net sales of $13.46 billion to $13.57 billion, up from its previous $13.4 billion&nbsp;to&nbsp;$13.55 billion range. However, it narrowed adjusted EBITDA margin guidance to&nbsp;between&nbsp;6.7%&nbsp;and&nbsp;6.8% from 6.6%&nbsp;to&nbsp;6.8%. Third-quarter&nbsp;(Q3)&nbsp;adjusted EBITDA margin is expected&nbsp;between 6.6%&nbsp;and&nbsp;6.7%.According to Investing.com, analysts&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/stock-market-news/why-is-chewy-stock-slipping-today-93CH-5586309">flagged</a> Chewy’s declining liquidity. Chewy ended Q2 with $611 million in cash, down from $860.1 million at fiscal year-end, while long-term debt stood at $588.7 million.<h2 class="st-heading-2">What Retail Investors Think About CHWY Stock?</h2>Retail traders remained upbeat despite the decline. Investor sentiment on Stocktwits surrounding CHWY turned ‘extremely bullish’ from ‘neutral’&nbsp;territory&nbsp;a week earlier, amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_09_09_202638_56d2291686.png" alt="Screenshot 2026-09-09 202638.png" width="825" height="456"><figcaption>CHWY stock retail sentiment on September 9 as of 10:57 a.m. ET | Source: Stocktwits</figcaption></figure>One Stocktwits user said they are waiting for a deeper pullback before considering re-entry, while watching for Chewy’s vet services and prescription businesses to gain traction.<stembedurl>https://stocktwits.com/Top_Dog_Pro_Trader/message/663860169</stembedurl>CHWY stock has fallen nearly 35% this year and almost 50% in the last 12 months.See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/analog-devices-to-acquire-alif-semiconductor-for-1-35-b-ceo-says-this-is-physical-intelligence-in-action/cZt75CARJzh">Analog Devices To Acquire Alif Semiconductor For $1.35B – CEO Says ‘This Is Physical Intelligence In Action’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone held in a hand shows the logo of Chewy Inc. (Source: Getty Images)

Chewy Inc. (CHWY) stock fell in morning trade on Wednesday, putting shares on track to hit an over one-month low, even as the company reported higher second-quarter sales and raised its full-year outlook.

Feed

News

Sentiment

Fundamentals

Info

PAWZ ProShares Pet Care ETF

Latest PAWZ News